Sign Up

Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk

Eli Lilly and Co. (NYSE:LLY) stock plunged on Thursday after the company released topline data from the Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

The trial included over 3,000 obese patients with a weight-related medical problem and without diabetes.

At 72 weeks, all three doses of orforglipron met the primary endpoint and all key secondary endpoints compared to placebo.

Also Read: Trump Administration Plan Signals Shift Toward Weight-Loss Drug Coverage For Medicare Patients

For the primary endpoint, orforglipron 36 mg lowered weight by an average of 12.4% (27.3 lbs) compared to 0.9% (2.2 lbs) with placebo using the efficacy estimand. CNBC writes that Wall Street’s expectations were around 15%.

59.6% of participants taking the highest dose of orforglipron lost at least 10% of their body weight, while 39.6% lost at least 15%.

For comparison, Novo Nordisk A/S’ (NYSE:NVO) oral semaglutide 25 mg achieved a 16.6% weight loss vs. a 2.7% reduction with placebo after ...